Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Shares Outstanding (2017 - 2025)

Arcus Biosciences has reported Shares Outstanding over the past 9 years, most recently at $125.3 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $125.3 million for Q4 2025, up 35.9% from a year ago — trailing twelve months through Dec 2025 was $125.3 million (up 35.9% YoY), and the annual figure for FY2025 was $125.3 million, up 35.9%.
  • Shares Outstanding for Q4 2025 was $125.3 million at Arcus Biosciences, up from $107.1 million in the prior quarter.
  • Over the last five years, Shares Outstanding for RCUS hit a ceiling of $125.3 million in Q4 2025 and a floor of $69.6 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $74.6 million (2023), compared with a mean of $83.9 million.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 56.93% in 2021 and later rose 2.09% in 2023.
  • Arcus Biosciences' Shares Outstanding stood at $70.8 million in 2021, then grew by 2.97% to $72.9 million in 2022, then grew by 3.57% to $75.5 million in 2023, then increased by 22.12% to $92.2 million in 2024, then surged by 35.9% to $125.3 million in 2025.
  • The last three reported values for Shares Outstanding were $125.3 million (Q4 2025), $107.1 million (Q3 2025), and $106.4 million (Q2 2025) per Business Quant data.